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examined. RESULTS: Approximately 26% (n = 7,354) 
of patients in SP1 were excluded from SP2. Reasons 
for exclusion were death (22%), loss to follow-up (34%),
and right-censoring (44%). Age, gender, and calendar
year of the index event were not dramatically different
between the two populations. Both crude and age-
adjusted prevalence rates of most comorbid conditions at
index date were lower in SP2. Incidence rates showed a
similar pattern. Mortality was signiﬁcantly higher in SP1
(5.7 vs. 3.8/100PY; p < 0.05). There was a decrease in
the proportion of patients never treated with drugs for
the selected condition from 42% in SP1 to 36% in SP2.
Mean and median values for annualized rates were lower
in SP2, possibly indicating that some patients with higher
resource use were selectively excluded. CONCLUSIONS:
The impact of selection bias associated with deﬁning
patient cohorts based on minimum follow-up time affects
both economic and epidemiologic analyses. Overall, the
results of this study suggest that researchers should deﬁne
a cohort without regard to follow-up whenever possible.
The appropriate and necessary follow-up period will
clearly vary by condition and perhaps by local practice
patterns. The data themselves can help inform the appro-
priate time frame for follow-up.
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AUTOMATING ECONOMIC ANALYSIS OF 
CO-MEDICATION USE IN CLINICAL TRIALS
Waldeck R1, Kawabata H2,Yuan Y2
1Bristol-Myers Squibb, Wallingford, CT, USA; 2Bristol-Myers
Squibb, Princeton, NJ, USA
OBJECTIVES: Resource utilization of co-medication use
in clinical trials is often cumbersome because it involves
thousands of co-medications, which are not assigned
standard codes, such as National Drug Codes (NDC),
making analysis difﬁcult at the individual drug level. We
developed an automated routine that allowed each 
co-medication to be matched to published NDC prices,
in turn allowing, costing at the individual drug level.
METHODS: Computer-based automated mapping rou-
tines (SAS, v8.2) were developed to handle co-medication
trial data collected using the World Health Organization’s
(WHO) Anatomical Therapeutic Chemical (ATC) classi-
ﬁcation system, along with the daily dose. Our approach
was to map the ATC code descriptions to their generic
names, and merge these with those in the Food and Drug
Administration’s (FDA) NDC table, thereby obtaining 
the NDC for each co-medication used. An average cost
was calculated by averaging the average wholesale 
price (AWP) per milligram for each NDC that matched
the generic names. The average daily cost for the co-
medications was then calculated by multiplying the daily
dose by the average costs. RESULTS: A random sample
of 1000 observations of co-medications data was drawn
from a randomized cardiovascular trial. This sample 
contained 238 unique WHO ATC codes. Our computer-
based automated procedures matched 209; i.e., about
88% of the codes. This translated into 956 out of the
1000 observations being matched (96%). Comparing the
entire trial dataset with NDC table showed a 92% match.
CONCLUSIONS: The proposed methodology provides
an automated routine allowing WHO ATC coded co-
medications to be transcribed to unique NDC codes. This
methodology can also be extended to handle medications
described as generic or brand names in any format. This
allows co-medication costs to be assigned at the individ-
ual drug level, improving the feasibility and rigor of
within-trial economic analysis.
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1Rutgers University, Piscataway, NJ, USA; 2Centers for
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OBJECTIVE: The objectives of this study were to
measure diabetic patients’ quality-of-life (QOL), utility,
and willingness-to-pay (WTP), and to examine the 
interrelationship between these measures. METHODS:
Diabetic patients ≥18 years old were randomly selected
from 2 hospital endocrinology clinics. Patients were inter-
viewed to measure utility values using a visual analogue
scale (VAS) and standard gamble (SG), and measure WTP
for pharmacist-provided education using contingent 
valuation. QOL was measured via self-administered 
questionnaire containing the 36-item Short-Form health
survey (SF-36), Diabetes Quality of Life instrument
(DQOL), and Health Utility Index (HUI). Relationships
between scales of QOL instruments, utilities, and WTP
were tested using Spearman’s correlation coefﬁcients and
regression analysis, and differences by study variables
were tested using t-tests and analysis of variance.
RESULTS: Two-hundred eighty-three patients completed
the interview and questionnaire. Mean health-utility was
0.72 from VAS, 0.83 from SG, 0.83 from HUI2 and 0.73
from HUI3. Mean scores for SF-36 physical component
(PCS) and mental component (MCS) were 45.4 and 50.2,
respectively, and mean score for total DQOL was 0.70.
Patients’ mean WTP was $32.65. Age and number of dia-
betic complications were signiﬁcant factors for VAS. The
PCS and MCS were both signiﬁcantly positively corre-
lated with total DQOL, HUI2, HUI3, and VAS (all p <
0.0001), but not SG or WTP. VAS and total DQOL were
signiﬁcantly correlated with each other, SF-36 subscales,
HUI2, HUI3, and SG (all p < 0.05), except for WTP. WTP
was neither signiﬁcantly correlated with any utility values
(VAS, SG, HUI2, and HUI3) nor any QOL measures 
(SF-36 and total DQOL), but correlations were in the
expected directions. CONCLUSIONS: The DQOL
demonstrated strong correlation with SF-36 and utility
values measured using VAS, SG, and HUIs, but weak 
correlation with WTP. Further research is warranted to
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RESPONSIVENESS OF PHYSICAL FUNCTION
MEASURES:TREATMENT WITH CTLA4IG 
(BMS-188667) IN PATIENTS WITH ACTIVE
RHEUMATOID ARTHRITIS
Li T,Williams GR, L’Italien G, Kawabata H, Nuamah I
Bristol-Myers Squibb, Princeton, NJ, USA
OBJECTIVES: To examine the treatment effect of
CTLA4Ig on physical function and to evaluate the
responsiveness of different domains of physical function
compared to tender joint count, a highly sensitive efﬁcacy
measure for rheumatoid arthritis (RA). METHODS: In a
randomized, double blind, placebo-controlled trial, 339
subjects with active RA receiving methotrexate (MTX)
were randomized to 3 treatment arms (CTLA4Ig 2 or 10
mg/kg and placebo) given intravenously once monthly.
The Modiﬁed Health Assessment Questionnaire (mHAQ)
was used to assess physical function and was adminis-
tered monthly. It consisted of questions assessing eight
domains of physical function: dressing, arising, eating,
walking, hygiene, reach, grip, and common activities.
Mean change from baseline in the mHAQ scores were
compared between the CTLA4Ig and the placebo groups.
Relative efﬁciency of mHAQ domains were calculated as
(SESmHAQ / SEStender joint count)2, with SES denotes standard-
ized effect size. A relative efﬁciency >1 suggested that the
domain was more efﬁcient than the tender joint count in
detecting the observed treatment effect. RESULTS: At 
6 months, the mHAQ summary score improved 42% 
for the CTLA4Ig 10mg/kg group compared to 14% for
the placebo group. This improvement was considered to
be clinically meaningful based on the commonly accepted
threshold. Patients in the 10mg/kg group also experi-
enced statistically signiﬁcant improvements compared to
the placebo group in the following domains: eating (32%
more improvement), hygiene (32% more), grip (24%
more), dressing (20% more), and walking (16% more).
Moreover, these physical domains were shown to be as
responsive as the tender joint count to detect a treatment
effect, with relative efﬁciencies close to one. CONCLU-
SIONS: treatment with CTLA4Ig signiﬁcantly improved
physical function in patients with active RA, especially in
areas related to eating, hygiene, grip, and walking ability.
Measures in physical function are efﬁcient in detecting
clinical improvements important to patients.
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OBJECTIVES: This study was conducted to measure dia-
betic patients’ willingness-to-pay (WTP) for diabetes edu-
cation provided by pharmacists utilizing the contingent
valuation method, to determine factors which inﬂuence
patients’ WTP, and to test starting point bias and scope
effects. METHODS: Diabetic patients, randomly selected
at 2 hospital endocrinology clinics, were interviewed 
to measure their WTP for education resulting in 3 
hypothetical risk-reductions in diabetic complications
(reduction from 75% without education to 37.5% with
education, 50%®25%, and 25%®12.5%) using a
bidding game with randomly assigned starting amounts
($10/$40). Sample mean (SM) and mean based on log-
normal distribution (LNM) were calculated. Mean WTP
was calculated using 2-part model (PM) with a smear 
estimator, and Heckman 2-stage model (HM) for sample
selection correction, which were further used to 
determine signiﬁcant factors inﬂuencing WTP amount.
RESULTS: A total of 283 patients were interviewed.
Patients’ mean age and household income was 53.5 years
and $60,202 respectively. In total, 59% of patients were
willing-to-pay. SMs were $36 ± $49 for 75%Æ37.5%;
$35 ± $50 for 50%Æ25%; and $26 ± $42 for
25%Æ12.5%. SMs were similar to LNMs. Means based
on HM were $41 ± $23 for the 75%Æ37.5%, $38 ± $19
for 50%Æ25%; and $27 ± $16 for 25%Æ12.5%, which
were nearly the same as means calculated based on PM.
In HM model, patients were willing-to-pay signiﬁcantly
larger amounts as risk-reduction level increased (P <
0.001), as starting amount increased (P < 0.001), and if
neuropathy was present (P < 0.001). Patients’ age, race,
hemoglobin A1c, type of diabetes, and history of retinopa-
thy were not signiﬁcant factors in predicting WTP
amount. CONCLUSIONS: Patients, on average, were
willing-to-pay between $26 and $41 for pharmacist 
provided diabetes education, depending on risk reduction
level (scope effect) and starting amounts (starting point
bias). The contingent valuation method is useful for 
determining the economic value of pharmacists’ educa-
tion. Further investigations are recommended to elucidate
factors inﬂuencing patients’ WTP for a variety of other
services.
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SMOKING STATUS AND HEALTH-RELATED
QUALITY OF LIFE (HRQOL): FINDINGS FROM
THE BEHAVIORAL RISK FACTOR
SURVEILLANCE SYSTEM (BRFSS) DATA
Mody RR, Smith MJ
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Smoking is one of the leading causes of
preventable mortality in the United States. The beneﬁts
of smoking cessation have been well documented, and
understanding the relationship between smoking and
